RBO & Co. LLC Raises Stock Position in Johnson & Johnson $JNJ

RBO & Co. LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 216,179 shares of the company's stock after purchasing an additional 2,605 shares during the quarter. Johnson & Johnson makes up approximately 5.7% of RBO & Co. LLC's holdings, making the stock its 3rd biggest holding. RBO & Co. LLC's holdings in Johnson & Johnson were worth $35,851,000 at the end of the most recent quarter.

• JNJ Stock Surge Signals Confidence in New Growth Path

Several other hedge funds also recently modified their holdings of JNJ. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC boosted its stake in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Topsail Wealth Management LLC bought a new position in Johnson & Johnson during the 4th quarter worth approximately $369,000. Voya Financial Advisors Inc. boosted its stake in Johnson & Johnson by 6.0% during the 4th quarter. Voya Financial Advisors Inc. now owns 4,998 shares of the company's stock worth $716,000 after acquiring an additional 282 shares during the last quarter. Finally, Cheviot Value Management LLC boosted its stake in Johnson & Johnson by 9.8% during the 4th quarter. Cheviot Value Management LLC now owns 155,318 shares of the company's stock worth $22,462,000 after acquiring an additional 13,823 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $179.0980 on Friday. The company's fifty day simple moving average is $163.48 and its 200-day simple moving average is $159.23. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $431.33 billion, a PE ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.

• 3 Big Dividend Plays With Strong Earnings to Back Them

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Wall Street Analysts Forecast Growth

• Worried About a Fading Rally? Consider These 3 Dividend Stocks

Several research analysts recently weighed in on JNJ shares. Guggenheim reissued a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. UBS Group lifted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Read Our Latest Stock Report on JNJ

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Read More

• Five stocks we like better than Johnson & Johnson
• Why Understanding Call Option Volume is Essential to Successful Options Trading
• MarketBeat Week in Review – 08/18 - 08/22
• Insider Selling Explained: Can it Inform Your Investing Choices?
• Royal Caribbean Earnings Beat Fuels Strong 2025 Outlook
• What is the Australian Securities Exchange (ASX)
• Alphabet’s Breakout Potential: From Laggard to AI Leader

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here